Showing results (491-500 of 834) with videos related to

Sort By:
Pageof 84
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
The New England Journal of Medicine|November 12, 2013
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney diseaseDick de Zeeuw, Tadao Akizawa, Paul Audhya, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
Diabetes, Obesity & Metabolism|October 13, 2021
Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trialUlrik Pedersen-Bjergaard, Rikke M Agesen, Julie M B Brøsen, et al.
The Lancet. Diabetes & Endocrinology|August 8, 2017
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysisKåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, et al.
Diabetes, Obesity & Metabolism|August 4, 2017
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational studyFrederik Persson, Thomas Nyström, Marit E Jørgensen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 3, 2024
Risk factor analysis for a rapid progression of chronic kidney diseaseAnne H S Vestergaard, Simon K Jensen, Uffe Heide-Jørgensen, et al.
Diabetes, Obesity & Metabolism|November 18, 2018
Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetesJesper Jensen, Morten Schou, Caroline Kistorp, et al.
European Journal of Heart Failure|January 17, 2025
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysisRobert J Mentz, Stefan D Anker, Bertram Pitt, et al.
Diabetes Care|December 19, 2015
Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical TrialMelanie J Davies, Stephen C Bain, Stephen L Atkin, et al.
Pageof 84